/
Oncology
Relapsed/refractory B-Cell Malignancies
6
Pipeline Programs↗
9
Active Trials↗
10
Companies Involved↗
Relapsed/Refractory B-cell Malignancies is an early-stage landscape with 6 programs across 10 companies. The most active players are Ubix Therapeutics, Inc., Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd, Nurix Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 16
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
16
clinical trials
Recruiting6 · 38%
Not yet recruiting3 · 19%
Unknown status3 · 19%
Completed2 · 13%
Approved for marketing1 · 6%
Terminated1 · 6%
Clinical Trials
Trial Activity
16 trials
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
Recruiting·—·N/A·NCT07345728·28 enrolled
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07240974·6 enrolled
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT07002112·30 enrolled
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07493174·86 enrolled
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT07763938·80 enrolled
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Unknown status·—·Phase 1·NCT05410041·15 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)